ORTIN GLOBAL liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−0.64×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.60×1.60×2.39×3.11×0.94×
1.60×1.60×2.38×3.09×0.56×
0.60.60.40.50.2
1.41.42.24.3−0.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ORTINGLOBE₹13.13

ORTIN GLOBAL LIMITED

· Pharma & Health
₹ CrorePeersLASAMANGALAMBIOFILCHEMVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹10.7 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————-0.64
Current Ratio0.943.112.391.601.60
Quick Ratio0.563.092.381.601.60
Cash, Equiv & ST Investments0.20.50.40.60.6
Working Capital-0.44.32.21.41.4
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.